Clinical Trial Detail

NCT ID NCT02119676
Title Study of Ruxolitinib in Colorectal Cancer Patients
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements no
Sponsors Incyte Corporation
Indications

colon adenocarcinoma

rectum adenocarcinoma

Therapies

Regorafenib

Ruxolitinib

Age Groups: adult

No variant requirements are available.